NSG 533 Advanced Pharmacology | Wilkes
University | Academic Year 2026/2027 | Test 1
Week 4
Section I: Pharmacokinetics
Question 1
A patient is prescribed an oral medication that undergoes extensive first-pass
metabolism. Which statement best describes the clinical implication of the first-
pass effect?
A. The drug has increased bioavailability because hepatic enzymes enhance its
active form
B. A significant portion of the oral dose is metabolized by the liver before reaching
systemic circulation, reducing bioavailability
C. The drug is primarily excreted unchanged by the kidneys, requiring dose
adjustment in renal impairment
D. The drug crosses the blood-brain barrier more efficiently due to hepatic
biotransformation
Correct Answer: B
Rationale: The first-pass effect occurs when orally administered drugs are
absorbed through the GI tract and carried by the portal vein directly to the liver,
where they undergo significant metabolism before reaching systemic circulation.
This reduces the bioavailability (fraction of the dose that reaches circulation) of
the drug. Drugs with high first-pass metabolism (e.g., morphine, verapamil,
propranolol) may require higher oral doses or alternative routes. Option A is
incorrect because first-pass metabolism reduces, not increases, bioavailability.
Option C describes renal excretion, not hepatic metabolism. Option D is unrelated
to first-pass metabolism.
Question 2
,A patient with advanced liver cirrhosis is prescribed a medication that is highly
protein-bound (98%). Which pharmacokinetic change is most likely to occur in this
patient?
A. Increased free drug fraction due to decreased albumin production, increasing
the risk of drug toxicity
B. Decreased free drug fraction due to increased plasma protein synthesis in
response to liver injury
C. No change in drug distribution because protein binding is unaffected by liver
disease
D. Increased volume of distribution due to enhanced tissue binding of the drug
Correct Answer: A
Rationale: In advanced liver cirrhosis, hepatic synthesis of albumin (the
primary plasma protein that binds acidic drugs) is significantly reduced. With less
albumin available, the free (unbound) fraction of highly protein-bound drugs
increases. The free drug is pharmacologically active, so this increases the risk of
drug toxicity at standard doses. Dose reduction may be necessary. Option B is
incorrect because liver disease decreases protein synthesis. Option C is false
because protein binding is directly affected. Option D is less relevant; the primary
concern is increased free drug concentration.
Question 3
A 78-year-old patient is prescribed a renally cleared medication. Which
pharmacokinetic consideration is most important for this patient?
A. Increased first-pass metabolism requiring higher oral doses
B. Decreased GFR associated with aging, which may require dose reduction to
prevent drug accumulation and toxicity
C. Enhanced protein binding due to increased albumin production in the elderly
D. Faster hepatic Phase II conjugation reactions increasing drug metabolism
Correct Answer: B
, Rationale: Aging is associated with a progressive decline in glomerular
filtration rate (GFR), which reduces renal clearance of drugs eliminated primarily
by the kidneys. Without dose adjustment, renally cleared drugs accumulate in
elderly patients, increasing the risk of toxicity. This is one of the most important
pharmacokinetic considerations in geriatric pharmacotherapy. Option A describes
hepatic changes, not renal. Option C is incorrect because albumin production
actually decreases with age. Option D is incorrect because hepatic metabolism
generally slows with aging.
Question 4
A patient is prescribed a medication metabolized primarily by CYP3A4. Which
combination would most likely increase the risk of drug toxicity?
A. Coadministration with a CYP3A4 inducer
B. Coadministration with a CYP3A4 inhibitor
C. Coadministration with a drug that enhances renal filtration
D. Coadministration with a drug that increases gastric motility
Correct Answer: B
Rationale: CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin,
grapefruit juice) reduce the metabolism of drugs that are CYP3A4 substrates,
leading to increased plasma concentrations and potential toxicity. In contrast,
CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John's wort) increase
metabolism, reducing drug levels and potentially causing therapeutic failure.
Options C and D do not directly affect CYP3A4-mediated metabolism.
Question 5
Which pharmacokinetic parameter describes the time it takes for a drug's plasma
concentration to decrease by half?
A. Bioavailability
B. Half-life
, C. Steady state
D. Volume of distribution
Correct Answer: B
Rationale: Half-life (t½) is the time required for the plasma concentration
of a drug to decrease by 50%. It determines dosing intervals and the time to reach
steady state (approximately 4–5 half-lives). Bioavailability refers to the fraction of
an administered dose that reaches systemic circulation. Steady state is the point
at which drug intake equals drug elimination. Volume of distribution is a
theoretical volume relating total drug amount in the body to plasma
concentration.
Question 6
A patient is started on a drug with a half-life of 12 hours. Approximately how long
will it take to reach steady-state plasma concentration?
A. 12 hours
B. 24 hours
C. 48–60 hours
D. 96 hours
Correct Answer: C
Rationale: Steady state is typically reached after approximately 4–5 half-
lives. For a drug with a half-life of 12 hours, this would be 4 × 12 = 48 hours to 5 ×
12 = 60 hours. Option A represents one half-life, which is insufficient. Option B
represents two half-lives. Option D represents eight half-lives, which is longer
than necessary.
Question 7
Which of the following routes of administration bypasses the first-pass effect?
A. Oral
B. Rectal (lower portion)
University | Academic Year 2026/2027 | Test 1
Week 4
Section I: Pharmacokinetics
Question 1
A patient is prescribed an oral medication that undergoes extensive first-pass
metabolism. Which statement best describes the clinical implication of the first-
pass effect?
A. The drug has increased bioavailability because hepatic enzymes enhance its
active form
B. A significant portion of the oral dose is metabolized by the liver before reaching
systemic circulation, reducing bioavailability
C. The drug is primarily excreted unchanged by the kidneys, requiring dose
adjustment in renal impairment
D. The drug crosses the blood-brain barrier more efficiently due to hepatic
biotransformation
Correct Answer: B
Rationale: The first-pass effect occurs when orally administered drugs are
absorbed through the GI tract and carried by the portal vein directly to the liver,
where they undergo significant metabolism before reaching systemic circulation.
This reduces the bioavailability (fraction of the dose that reaches circulation) of
the drug. Drugs with high first-pass metabolism (e.g., morphine, verapamil,
propranolol) may require higher oral doses or alternative routes. Option A is
incorrect because first-pass metabolism reduces, not increases, bioavailability.
Option C describes renal excretion, not hepatic metabolism. Option D is unrelated
to first-pass metabolism.
Question 2
,A patient with advanced liver cirrhosis is prescribed a medication that is highly
protein-bound (98%). Which pharmacokinetic change is most likely to occur in this
patient?
A. Increased free drug fraction due to decreased albumin production, increasing
the risk of drug toxicity
B. Decreased free drug fraction due to increased plasma protein synthesis in
response to liver injury
C. No change in drug distribution because protein binding is unaffected by liver
disease
D. Increased volume of distribution due to enhanced tissue binding of the drug
Correct Answer: A
Rationale: In advanced liver cirrhosis, hepatic synthesis of albumin (the
primary plasma protein that binds acidic drugs) is significantly reduced. With less
albumin available, the free (unbound) fraction of highly protein-bound drugs
increases. The free drug is pharmacologically active, so this increases the risk of
drug toxicity at standard doses. Dose reduction may be necessary. Option B is
incorrect because liver disease decreases protein synthesis. Option C is false
because protein binding is directly affected. Option D is less relevant; the primary
concern is increased free drug concentration.
Question 3
A 78-year-old patient is prescribed a renally cleared medication. Which
pharmacokinetic consideration is most important for this patient?
A. Increased first-pass metabolism requiring higher oral doses
B. Decreased GFR associated with aging, which may require dose reduction to
prevent drug accumulation and toxicity
C. Enhanced protein binding due to increased albumin production in the elderly
D. Faster hepatic Phase II conjugation reactions increasing drug metabolism
Correct Answer: B
, Rationale: Aging is associated with a progressive decline in glomerular
filtration rate (GFR), which reduces renal clearance of drugs eliminated primarily
by the kidneys. Without dose adjustment, renally cleared drugs accumulate in
elderly patients, increasing the risk of toxicity. This is one of the most important
pharmacokinetic considerations in geriatric pharmacotherapy. Option A describes
hepatic changes, not renal. Option C is incorrect because albumin production
actually decreases with age. Option D is incorrect because hepatic metabolism
generally slows with aging.
Question 4
A patient is prescribed a medication metabolized primarily by CYP3A4. Which
combination would most likely increase the risk of drug toxicity?
A. Coadministration with a CYP3A4 inducer
B. Coadministration with a CYP3A4 inhibitor
C. Coadministration with a drug that enhances renal filtration
D. Coadministration with a drug that increases gastric motility
Correct Answer: B
Rationale: CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin,
grapefruit juice) reduce the metabolism of drugs that are CYP3A4 substrates,
leading to increased plasma concentrations and potential toxicity. In contrast,
CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John's wort) increase
metabolism, reducing drug levels and potentially causing therapeutic failure.
Options C and D do not directly affect CYP3A4-mediated metabolism.
Question 5
Which pharmacokinetic parameter describes the time it takes for a drug's plasma
concentration to decrease by half?
A. Bioavailability
B. Half-life
, C. Steady state
D. Volume of distribution
Correct Answer: B
Rationale: Half-life (t½) is the time required for the plasma concentration
of a drug to decrease by 50%. It determines dosing intervals and the time to reach
steady state (approximately 4–5 half-lives). Bioavailability refers to the fraction of
an administered dose that reaches systemic circulation. Steady state is the point
at which drug intake equals drug elimination. Volume of distribution is a
theoretical volume relating total drug amount in the body to plasma
concentration.
Question 6
A patient is started on a drug with a half-life of 12 hours. Approximately how long
will it take to reach steady-state plasma concentration?
A. 12 hours
B. 24 hours
C. 48–60 hours
D. 96 hours
Correct Answer: C
Rationale: Steady state is typically reached after approximately 4–5 half-
lives. For a drug with a half-life of 12 hours, this would be 4 × 12 = 48 hours to 5 ×
12 = 60 hours. Option A represents one half-life, which is insufficient. Option B
represents two half-lives. Option D represents eight half-lives, which is longer
than necessary.
Question 7
Which of the following routes of administration bypasses the first-pass effect?
A. Oral
B. Rectal (lower portion)
